Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | iDFS by prior systemic treatment in NATALEE

Nicholas McAndrew • 16 Sep 2024
ESMO 2024
Breast Cancer Ribociclib Tamoxifen
NATALEE

Nicholas McAndrew, MD, MSCE, UCLA Health, Santa Monica, CA, discusses the results of the NATALEE trial (NCT03701334), which met its primary endpoint by demonstrating a significant invasive disease-free survival (iDFS) benefit with ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) versus NSAI alone in patients with HR+/HER2− early breast cancer. The benefit was sustained with longer follow-up. The analysis considered prior chemotherapy and endocrine therapy, showing that the iDFS advantage with RIB + NSAI was consistent across different prior treatments. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nicholas McAndrew

Assessing risk and treatment options in HR+/HER2- breast cancer
1:31
Assessing risk and treatment options in HR+/HER2- breast cancer
Nicholas McAndrew • 20 Oct 2025
Which patients with breast cancer benefit most from adjuvant CDK4-6 inhibitors?
2:26
Which patients with breast cancer benefit most from adjuvant CDK4-6 inhibitors?
Nicholas McAndrew • 20 Oct 2025
Key insights on trastuzumab deruxtecan in high-risk early breast cancer
1:35
Key insights on trastuzumab deruxtecan in high-risk early breast cancer
Nicholas McAndrew • 20 Oct 2025
Neoadjuvant chemo response and ribociclib outcomes in HR+/HER2- EBC
4:24
Neoadjuvant chemo response and ribociclib outcomes in HR+/HER2- EBC
Nicholas McAndrew • 20 Oct 2025

Related Videos

ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
Genomic assays and chemotherapy decisions in node-positive breast cancer
1:35
Genomic assays and chemotherapy decisions in node-positive breast cancer
Kevin Kalinsky • 31 May 2026
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
1:30
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
Yeon Hee Park • 31 May 2026
The content of VJOncology is intended for healthcare professionals